Mixing an electrochemically active cathode material powder (left) with a new fluorine-free binder (middle) and a nontoxic ...

Estuary Biotherapeutics, which is developing gene therapies to treat kidney disease, has launched with $103 million in ...

A ruthenium-based reaction exploits the stronger carbon-deuterium bond to enrich one mirror-image form from a racemic mixture ...

Max M. Hansmann, an organic chemist at the Technical University of Dortmund who also works on carbon-atom transfer reactions, ...

Biotechs in the US and Europe face challenges, but as a recent panel discussion made clear, the competition offers global ...

Finally, we should be worried about how these trial markets could impact public perception of the drug development and ...

In one of the largest tests to date, researchers find that satellites reliably spot the greenhouse gas across the board ...

HydRegen’s scientists are commercializing hydrogenase systems that work in conventional chemical reactors. Credit: HydRegen Enzymes are powerful tools for chemical synthesis, but their natural setting ...

Over $1 billion sat unused in US National Science Foundation (NSF) accounts as fiscal 2026 came to a close Oct. 1. A White ...

After successfully completing our previous strategic plan, we developed a new strategic plan in 2025. At its heart is our ...

Estuary is now plotting human trials that will begin in 2027 and 2028. The first will test EST-201, a Pkd2 gene therapy for ...

One compound they screened, azo-morphine-3 (AM-3), showed high affinity and high potency for the μ-opioid receptor (MOR).